Her main research focuses on the precision treatment of digestive system tumors and translational research as well as clinical research on new anticancer drugs. She has established an innovative system for clinical and translational research on digestive system tumors. She led over 100 international/domestic multicenter clinical research as Leading PI, which promoted the establishment of multiple guidelines for the diagnosis and treatment of digestive tract cancer in Asia and China. As the first or corresponding author, she has published over 250 SCI papers in Nature, Lancet, BMJ, JAMA, Nature Medicine, etc., and ranked as the World’s Top 2% most-cited Scientists. Invited by Nature Medicine to elucidate current status and future directions of oncology diagnosis/therapeutics in China. Authored 54 international/national clinical practice guidelines. Granted 18 national patents, achieving technology transfer commercialization valued at RMB 12.6 million. She has been awarded many prizes including the First Prize of Chinese Medical Science and Technology Award and the First Prize of China Anti-Cancer Association (CACA) Science and Technology Award.

Professor Lin Shen is the director of the Department of Gastrointestinal Oncology and Department of Early Drug Development Center, Peking University Cancer Hospital & Institute. She is also director of the Beijing Key Laboratory of Cell and Gene Therapy for Solid Tumors. She serves as secretary general of Gastric cancer association, China Anti-Cancer Association (CACA); standing member of the Chinese Society of Clinical Oncology (CSCO); and vice president of China Medical Women's Association (CMWA), etc.